News | March 09, 2023
Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
Resomer used in commercial 3D-printed implants for both soft and hard tissue applications
Resomer used in commercial 3D-printed implants for both soft and hard tissue applications
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Blanda will be responsible for overseeing Evonik’s amino acids and functional feed additives business and the expansion of its precision livestock farming approach
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)